when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Pulmonology · news · pharmadog

← back to Pulmonology

News · Pulmonology

513 stories

Jul 27, 26AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidatesfiercebiotech

Jul 27, 26Summit, Merck must navigate new regulatory terrain in China-first cancer landscapebiospace

Jul 27, 26American Regent, Inc. Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection, USP 60 mg/ 2 mL Due to the Presence of Visible Particulate Matterfda medwatch

Jul 24, 26Summit has less than a year of cash runway left as PD-1/VEGF verdict nearsbiospace

Jul 24, 26Baxter Issues Voluntary Nationwide Recall of Cefazolin in Dextrose Injection, USP, 2G / 100ml(20mg /ml) Single-Dose Infusion Bag in 100ml Due to Particulate Matter Found in Solutionfda recalls

Jul 24, 26BAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG / ML) SINGLE-DOSE INFUSION BAG IN 100ML DUE TO PARTICULATE MATTER FOUND IN SOLUTIONfda recalls

Jul 23, 26Chutes & Ladders—Biogen R&D vet gets in Formationfiercebiotech

Jul 23, 26FDA panel confronting peptide controversystat

Jul 23, 26GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drugbiospace

Jul 22, 26GSK lung cancer drug gets speedy approval following $10.6B dealbiopharma dive

Jul 22, 26FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyoutendpoints

Jul 22, 26Summit and Akeso sharpen case for ivonescimab with new Western databiospace

Jul 22, 26STAT+: Pharma tries to tamp down broad China restrictionsstat

Jul 22, 26Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease studybiopharma dive

Jul 22, 26As Maui recovers from devastating fires, a study offers vision for new rural health modelstat

Jul 22, 26Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readoutsbiospace

Jul 21, 26Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ reviewbiospace

Jul 21, 26Opinion: Science and the public are learning the wrong lessons from Covidstat

Jul 20, 26BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’fiercebiotech

Jul 20, 26Opinion: My husband’s suicide shows there’s something very wrong with the U.S. insurance industrystat

Jul 18, 26Opinion: Beware the unintended consequences of testosterone screening for military servicemembersstat

Jul 17, 26Opinion: What the 20th-century war on smog tells us about today’s wildfire smokestat

Jul 17, 26Quitting smoking is hard. A Medicare change may push doctors to give more helpstat

Jul 17, 26STAT+: The end for GSK’s chronic cough treatmentstat

Jul 17, 26Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advancesbiopharma dive

Jul 17, 26GSK shelves cough drug acquired in $2B dealbiopharma dive

Jul 17, 26How well are AI-discovered drugs faring in the clinic?biopharma dive

Jul 17, 26BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fieldsfiercebiotech

Jul 17, 26Insmed moves closer to $6B opportunity as PAH drug shows long-term durabilitybiospace

Jul 17, 26GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyoutendpoints

← prevpage 11 of 18next →